CMS Allows Local Contractors Latitude For SCD Risk-Assessor
This article was originally published in The Gray Sheet
Executive Summary
After cardiologists strongly urged CMS to support MWTA testing using the modified moving average method to determine if patients are at risk of sudden cardiac death, CMS left an opening for local Medicare contractors to decide on coverage rather than retaining a national non-coverage policy.
You may also be interested in...
CMS Says No, Again, To Modified Moving Average T-Wave Alternans Testing
In a new proposed decision memo, CMS says it plans to confirm its existing national non-coverage policy on microvolt T-wave alternans diagnostic testing with the modified moving average method.
CMS Considers Coverage For GE’s Risk-Predictor Tool For Sudden Cardiac Death
The Medicare agency says it is reconsidering a 2008 national noncoverage policy for GE Healthcare’s microvolt T-Wave alternans testing tool for evaluating risk of sudden cardiac death, and the potential need for an ICD. An alternative MTWA technique is already covered, but the company that makes that product is going out of business.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.